All In Biotech

Drug Trial Radar · NCT04056689

Study to Evaluate DNL151 in Subjects With Parkinson's Disease

A Phase 1b, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Determine the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL151 in Subjects With Parkinson's Disease

Last checked: Nov 19, 2026Latest source record: Apr 18, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

36

Actual

Start

Jul 23, 2019

Primary completion

Dec 2, 2020

Study completion Dec 2, 2020

Sponsor

Lead sponsor
BiogenBiogen (BIIB)
Sponsor type
Industry
First posted
Aug 14, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 30 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple oral doses of DNL151 in subjects with Parkinson's disease.

Conditions

  • Parkinson's Disease

Interventions

  • DNL151Drug

    Oral repeating dose

  • PlaceboDrug

    Oral repeating dose

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Subjects with Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: Randomization to Day 42
  2. Number of Subjects with laboratory test abnormalitiesTime frame: Randomization to Day 42
  3. Number of Subjects with vital sign abnormalitiesTime frame: Randomization to Day 42
  4. Number of Subjects with electrocardiogram (ECG) abnormalitiesTime frame: Randomization to Day 42
  5. Number of Subjects with clinically significant neurological examination abnormalitiesTime frame: Randomization to Day 42

Locations

8 sites in 4 countries. Site status is shown where the registry gives one.

  • PPD Clinical Research Unit

    Orlando, Florida

  • Quest Research Institute

    Farmington Hills, Michigan

  • UZ Leuven

    Leuven, Belgium

  • QPS

    Leeuwarden, Netherlands

  • Centre for Human Drug Research

    Leiden, South Holland, Netherlands

  • Royal Liverpool University Hospital

    Liverpool, United Kingdom

  • MAC Clinical Research

    Manchester, United Kingdom

  • Simbec-Orion Clinical Pharmacology

    Merthyr Tydfil, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.